D. Boral Capital Reaffirms Buy Rating for UroGen Pharma (NASDAQ:URGN)
UroGen Pharma (NASDAQ:URGN – Get Free Report)‘s stock had its “buy” rating restated by D. Boral Capital in a report issued on Thursday,Benzinga reports. They currently have a $25.00 target price on the stock. D. Boral Capital’s price objective points to a potential upside of 107.81% from the company’s current price. Other equities research analysts […]
UroGen Pharma (NASDAQ:URGN – Get Free Report)‘s stock had its “buy” rating restated by D. Boral Capital in a report issued on Thursday,Benzinga reports. They currently have a $25.00 target price on the stock. D. Boral Capital’s price objective points to a potential upside of 107.81% from the company’s current price. Other equities research analysts […]
